What's Left In $400M Skinny Label Row? A Lot, Court Says

By Theresa Schliep

A number of key issues remain live in the $400 million fight between Teva Pharmaceuticals and GlaxoSmithKline over whether the generic-drug maker induced healthcare providers to infringe the brand-name company's heart drug patent, including the availability of a new trial, a Delaware federal judge has said.

 Opinion attached | Read full article » | Save to favorites »